PMLRARα Binds to Fas and Suppresses Fas-mediated Apoptosis Through Recruiting C-FLIP in Vivo

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2011 Aug 2

PMID 21803845

Citations 5

Authors

Rong-Hua Tao

Zuzana Berkova

Jillian F Wise

Abdol-Hossein Rezaeian

Urszula Daniluk

Xue Ao

David H Hawke

Judith E Karp

Hui-Kuan Lin

Jeffrey J Molldrem

Felipe Samaniego

Affiliations

Soon will be listed here.

Abstract

Defective Fas signaling leads to resistance to various anticancer therapies. Presence of potential inhibitors of Fas which could block Fas signaling can explain cancer cells resistance to apoptosis. We identified promyelocytic leukemia protein (PML) as a Fas-interacting protein using mass spectrometry analysis. The function of PML is blocked by its dominant-negative form PML-retinoic acid receptor α (PMLRARα). We found PMLRARα interaction with Fas in acute promyelocytic leukemia (APL)-derived cells and APL primary cells, and PML-Fas complexes in normal tissues. Binding of PMLRARα to Fas was mapped to the B-box domain of PML moiety and death domain of Fas. PMLRARα blockage of Fas apoptosis was demonstrated in U937/PR9 cells, human APL cells and transgenic mouse APL cells, in which PMLRARα recruited c-FLIP(L/S) and excluded procaspase 8 from Fas death signaling complex. PMLRARα expression in mice protected the mice against a lethal dose of agonistic anti-Fas antibody (P < .001) and the protected tissues contained Fas-PMLRARα-cFLIP complexes. Taken together, PMLRARα binds to Fas and blocks Fas-mediated apoptosis in APL by forming an apoptotic inhibitory complex with c-FLIP. The presence of PML-Fas complexes across different tissues implicates that PML functions in apoptosis regulation and tumor suppression are mediated by direct interaction with Fas.

Citing Articles

CD74-AKT Axis Is a Potential Therapeutic Target in Triple-Negative Breast Cancer.

Wang J, Huang D, Nguyen T, Phan L, Wei W, Rezaeian A Biology (Basel). 2024; 13(7).

PMID: 39056676 PMC: 11274071. DOI: 10.3390/biology13070481.

Exercise Inhibits Doxorubicin-Induced Damage to Cardiac Vessels and Activation of Hippo/YAP-Mediated Apoptosis.

Tao R, Kobayashi M, Yang Y, Kleinerman E Cancers (Basel). 2021; 13(11).

PMID: 34205942 PMC: 8198139. DOI: 10.3390/cancers13112740.

CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.

Berkova Z, Wang S, Ao X, Wise J, Braun F, Rezaeian A J Exp Clin Cancer Res. 2014; 33:80.

PMID: 25304249 PMC: 4210479. DOI: 10.1186/s13046-014-0080-y.

Extrinsic apoptosis is impeded by direct binding of the APL fusion protein NPM-RAR to TRADD.

Chattopadhyay A, Hood B, Conrads T, Redner R Mol Cancer Res. 2014; 12(9):1283-91.

PMID: 25033841 PMC: 4163521. DOI: 10.1158/1541-7786.MCR-14-0080.

Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.

Wise J, Berkova Z, Mathur R, Zhu H, Braun F, Tao R Blood. 2013; 121(23):4729-39.

PMID: 23599269 PMC: 3674671. DOI: 10.1182/blood-2012-12-471094.

References

Fulda S, Meyer E, Friesen C, Susin S, Kroemer G, Debatin K . Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene. 2001; 20(9):1063-75. DOI: 10.1038/sj.onc.1204141. View

Janin A, Deschaumes C, Daneshpouy M, Estaquier J, Micic-Polianski J, Akarid K . CD95 engagement induces disseminated endothelial cell apoptosis in vivo: immunopathologic implications. Blood. 2002; 99(8):2940-7. DOI: 10.1182/blood.v99.8.2940. View

Tussie-Luna M, Rozo L, Roy A . Pro-proliferative function of the long isoform of PML-RARalpha involved in acute promyelocytic leukemia. Oncogene. 2006; 25(24):3375-86. DOI: 10.1038/sj.onc.1209388. View

Early E, Moore M, Kakizuka A, MARTIN P, Evans R, Dmitrovsky E . Transgenic expression of PML/RARalpha impairs myelopoiesis. Proc Natl Acad Sci U S A. 1996; 93(15):7900-4. PMC: 38846. DOI: 10.1073/pnas.93.15.7900. View

Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W . The function of PML in p53-dependent apoptosis. Nat Cell Biol. 2000; 2(10):730-6. DOI: 10.1038/35036365. View

Testa U, Grignani F, Samoggia P, Zanetti C, Riccioni R, Coco F . The PML/RARalpha fusion protein inhibits tumor necrosis factor-alpha-induced apoptosis in U937 cells and acute promyelocytic leukemia blasts. J Clin Invest. 1998; 101(10):2278-89. PMC: 508816. DOI: 10.1172/JCI1332. View

Kitareewan S, Pitha-Rowe I, Sekula D, Lowrey C, Nemeth M, Golub T . UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99(6):3806-11. PMC: 122605. DOI: 10.1073/pnas.052011299. View

Lin H, Bergmann S, Pandolfi P . Cytoplasmic PML function in TGF-beta signalling. Nature. 2004; 431(7005):205-11. DOI: 10.1038/nature02783. View

Kakizuka A, Miller Jr W, Umesono K, Warrell Jr R, Frankel S, Murty V . Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991; 66(4):663-74. DOI: 10.1016/0092-8674(91)90112-c. View

10.

Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H . PML nuclear bodies and apoptosis. Oncogene. 2004; 23(16):2819-24. DOI: 10.1038/sj.onc.1207533. View

11.

Gurrieri C, Capodieci P, Bernardi R, Scaglioni P, Nafa K, Rush L . Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst. 2004; 96(4):269-79. DOI: 10.1093/jnci/djh043. View

12.

Kamitani T, Nguyen H, Kito K, Yeh E . Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem. 1998; 273(6):3117-20. DOI: 10.1074/jbc.273.6.3117. View

13.

Day T, Huang S, Safa A . c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol. 2008; 76(12):1694-704. PMC: 2610355. DOI: 10.1016/j.bcp.2008.09.007. View

14.

Bernardi R, Pandolfi P . Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene. 2003; 22(56):9048-57. DOI: 10.1038/sj.onc.1207106. View

15.

Ferrucci P, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A . The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 1993; 74(3):423-31. DOI: 10.1016/0092-8674(93)80044-f. View

16.

Ariumi Y, Ego T, Kaida A, Matsumoto M, Pandolfi P, Shimotohno K . Distinct nuclear body components, PML and SMRT, regulate the trans-acting function of HTLV-1 Tax oncoprotein. Oncogene. 2003; 22(11):1611-9. DOI: 10.1038/sj.onc.1206244. View

17.

van Blitterswijk W, Klarenbeek J, van der Luit A, Alderliesten M, van Lummel M, Verheij M . Fas/CD95 down-regulation in lymphoma cells through acquired alkyllysophospholipid resistance: partial role of associated sphingomyelin deficiency. Biochem J. 2009; 425(1):225-34. DOI: 10.1042/BJ20090455. View

18.

Budd R, Yeh W, Tschopp J . cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol. 2006; 6(3):196-204. DOI: 10.1038/nri1787. View

19.

Muller M, Scaffidi C, Galle P, Stremmel W, Krammer P . The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. Eur Cytokine Netw. 1999; 9(4):685-6. View

20.

Dellaire G, Bazett-Jones D . PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays. 2004; 26(9):963-77. DOI: 10.1002/bies.20089. View